American Society of Hematology

Figure 2.

$PFS of relapsed/refractory TFH vs non-TFH phenotype PTCL after front-line chemotherapy, of which 25% underwent high-dose chemotherapy and autologous stem cell rescue. PFS was 7.3 months for the TFH patients and 5.3 months for the non-TFH phenotype patients; log rank P = .65 (HR 1.39 for non-TFH; 95% CI, 0.98-1.99).$

PFS of relapsed/refractory TFH vs non-TFH phenotype PTCL after front-line chemotherapy, of which 25% underwent high-dose chemotherapy and autologous stem cell rescue. PFS was 7.3 months for the TFH patients and 5.3 months for the non-TFH phenotype patients; log rank P = .65 (HR 1.39 for non-TFH; 95% CI, 0.98-1.99).

This Feature Is Available To Subscribers Only